לנלידומיד תרו 20 מג
taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 20 mg - lenalidomide
לנלידומיד תרו 25 מג
taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 25 mg - lenalidomide
לנלידומיד תרו 5 מג
taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 5 mg - lenalidomide
לנלידומיד תרו 7.5 מג
taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 7.5 mg - lenalidomide
רבלימיד 5 מ"ג
neopharm scientific ltd - lenalidomide 5 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 10 מ"ג
neopharm scientific ltd - lenalidomide 10 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 15 מ"ג
neopharm scientific ltd - lenalidomide 15 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 25 מ"ג
neopharm scientific ltd - lenalidomide 25 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
נינלארו 2.3 מג
takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 2.3 mg - ixazomib
נינלארו 2.3 מג
takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 2.3 mg - ixazomib